RESUMO
A trial has been conducted of recombinant alpha 2-interferon (reaferon) used in 32 patients with Ph'[correction of Rh']-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed. The treatment lasted from 2 months to 3 years. Clinicohematological remission was confirmed conventionally and by the degree of Ph'-positive clone reduction. An attempt is made to clarify the mechanism underlying the resistance to reaferon basing on the immunological data (detection of antireaferon neutralizing antibodies). The authors propose a combined treatment (myelosan plus reaferon) of CML which has obvious advantages over myelosan monotherapy.
Assuntos
Crise Blástica/terapia , Interferon Tipo I/uso terapêutico , Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia , Adolescente , Adulto , Idoso , Crise Blástica/sangue , Criança , Doença Crônica , Avaliação de Medicamentos , Feminino , Humanos , Interferon Tipo I/efeitos adversos , Interferon Tipo I/farmacocinética , Interferon alfa-2 , Interferon-alfa , Leucemia Mielogênica Crônica BCR-ABL Positiva/sangue , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Masculino , Pessoa de Meia-Idade , Proteínas Recombinantes , Indução de RemissãoRESUMO
The described basophilic variant of CML in blastic crisis was characterized by a distinct hyperhistaminemia, a moderate hypocoagulation and an insufficiently effective cytostatic therapy. Cell kinetic was characterized by a marked diminution of the whole marketing index (with H3-thymidine) of blasts and immature basophils with simultaneous prolongation of the generation time in comparison to myeloblasts at the chronic stage of the CML. Aneuploid cell clones prevailed in the bone-marrow.